Last reviewed · How we verify
HU007
HU007 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
HU007 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HU007 |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
HU007 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Hypoglycemia
Key clinical trials
- HU007 in Patients with Dry Eye Syndrome (PHASE3)
- HU007 Eye Drops in Patients With Dry Eye Syndrome (PHASE3)
- Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome (PHASE3)
- Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HU007 CI brief — competitive landscape report
- HU007 updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI